Five Questions For Boehringer Ingelheim's Data Boss
This article was originally published in Scrip
Executive Summary
The end of 2015 saw Boehringer Ingelheim follow a number of its pharmaceutical peers by bringing in an external service provider – in this case Medidata Solutions – to meet its cloud technology and data analysis needs. Scrip spoke with Klaus Stern, global head of biostatistics and data sciences at Boehringer, to find out why fortifying the company's internal R&D efforts with external cutting-edge technology was so vital.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.